Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144568 | 1.00 | SMARCA2 (0.48) | SMARCA2SMARCA4ERBB2KCNQ3KCNQ2 | |
| SCHEMBL5142699 | 0.92 | KCNQ3 (0.48) | SMARCA2SMARCA4ERBB2KCNQ3KCNQ2 | |
| SCHEMBL5142697 | 0.92 | KCNQ3 (0.48) | SMARCA2SMARCA4ERBB2KCNQ3KCNQ2 | |
| SCHEMBL5142373 | 0.91 | ERBB2 (0.49) | ERBB2KMT2AMEN1TSHRLMNA | |
| SCHEMBL5142605 | 0.88 | ERBB2 (0.48) | SMARCA2SMARCA4ERBB2KMT2AMEN1 | |
| SCHEMBL5142608 | 0.88 | ERBB2 (0.48) | SMARCA2SMARCA4ERBB2KMT2AMEN1 | |
| SCHEMBL5141422 | 0.88 | KMT2A (0.50) | SMARCA2SMARCA4ERBB2KMT2AMEN1 | |
| SCHEMBL5141419 | 0.88 | KMT2A (0.50) | SMARCA2SMARCA4ERBB2KMT2AMEN1 | |
| SCHEMBL5142700 | 0.87 | KMT2A (0.52) | SMARCA2SMARCA4ERBB2KMT2AMEN1 | |
| SCHEMBL5142698 | 0.87 | KMT2A (0.52) | SMARCA2SMARCA4ERBB2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | claimed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CASP14, CASP2, CASP3 | SMARCA2 1938/4885SMARCA4 2622/4885ERBB2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.